Centauri Therapeutics
- | Biotech or pharma, therapeutic R&D
Centauri is developing novel immunotherapeutics with two MoAs, a moiety directly targeting cell surface proteins and a glycan effector domain which triggers a potent pre-existing polyclonal immune response increasing phagocytosis and complement fixation.
Address
MacclesfieldUnited Kingdom
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}